We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more

Chondroitin trials for osteoarthritis

Review article (2007)

In the 19 trials into the use of chondroitin for treating osteoarthritis assessed in this review article, the number of participants ranged from 46–631. The trials lasted between 13–132 weeks.

Sixteen trials compared the potential benefits of chondroitin with that of a placebo. The data from the other three came from conference abstracts, meaning only a summary of results is available or they had poorly defined comparison groups.

  • Twelve trials out of the 16 found that chondroitin was significantly superior to the placebo in relieving pain.
  • Five of the 16 placebo trials investigated the potential beneficial effect of chondroitin on increasing the width of joint space. Most found that chondroitin had a small and insignificant effect, compared to the placebo, on the progression of joint space narrowing.
  • Twelve of the 16 placebo trials found that the chondroitin was more effective than the placebo in terms of reducing painkiller use. The other four trials found that chondroitin and the placebo had similar effects.
  • The number and severity of side-effects reported by participants who received chondroitin was less than or similar to those taking the placebo in most of the trials.
  • Overall, evidence from trials with a good study design in putting participants in treatment groups and trials that used the most suitable statistical methods had lower estimates of effectiveness of chondroitin, particularly in terms of reduction in joint pain.

Trial 1

In this trial, 364 participants received either three 400 mg chondroitin sulphate capsules or one 300 mg avocado soybean unsaponifiable capsule a day for six months.

  • Both groups reported decreased pain and stiffness at the end of the trial and for two months afterwards, but there was no difference between the groups.
  • There was no difference in minor side-effects reported between the groups.

Trial 2

A second RCT randomly assigned 622 participants to receive either one 800 mg sachet of chondroitin sulphate or a sachet of placebo once a day for two years

  • After six months of treatment, those who received chondroitin sulphate reported a greater improvement in pain. Both participants’ and their doctors’ overall assessment suggested that the treatment was effective.
  • There were no differences between groups in stiffness and physical function and no differences between the groups at the end of the study.

Trial 3‡

The 662 participants of this study received one of the following doses three times a day for 24 months:

In comparison to the placebo, no treatment demonstrated improvement in pain or function.

Review article (2010)

The authors of the most recent review concluded that chondroitin (on its own or combined with glucosamine) didn’t reduce joint pain to any clinically meaningful extent or change clinical aspects of the joint.


0800 5200 520

Our new helpline: Call us for free information, help and advice on your type of arthritis. Open Mon–Fri 9am–8pm.

All calls are recorded for training and quality purposes

Virtual Assistant

Our new Arthritis Virtual Assistant uses artificial intelligence to answer your arthritis related questions 24/7.

Ask a question
For more information, go to
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.